Lenalidomide and low‐dose dexamethasone in Japanese patients with newly diagnosed multiple myeloma: A phase II study

In the FIRST trial (MM‐020), lenalidomide plus low‐dose dexamethasone (Rd) reduced the risk of disease progression or death compared with combination melphalan–prednisone–thalidomide. As the FIRST trial did not include any Japanese patients, the efficacy and safety of continuous treatment with Rd wa...

Descripción completa

Detalles Bibliográficos
Autores principales: Suzuki, Kenshi, Shinagawa, Atsushi, Uchida, Toshiki, Taniwaki, Masafumi, Hirata, Hirokazu, Ishizawa, Kenichi, Matsue, Kosei, Ogawa, Yoshiaki, Shimizu, Takayuki, Otsuka, Maki, Matsumoto, Morio, Iida, Shinsuke, Terui, Yasuhito, Matsumura, Itaru, Ikeda, Takashi, Takezako, Naoki, Ogaki, Yumi, Midorikawa, Shuichi, Houck, Vanessa, Ervin‐Haynes, Annette, Chou, Takaaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4970832/
https://www.ncbi.nlm.nih.gov/pubmed/26914369
http://dx.doi.org/10.1111/cas.12916

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4970832/
https://www.ncbi.nlm.nih.gov/pubmed/26914369
http://dx.doi.org/10.1111/cas.12916

Ejemplares similares